Table 2. Association of disease subtypes with plasma CRP levels^*.

	Pu†	Mean difference (95% CI)	Pm‡	Mean difference (95% CI)	Pu, §	Mean difference (95% CI)
Disease duration 1¶	0.303	0.07 (− 0.06, 0.19)	0.625	0.04 (−0.12, 0.20)	0.348	0.07 (−0.08, 0.22)
Disease duration 2#	0.809	0.005 (−0.03, 0.04)	0.854	−0.05 (−0.55, 0.46)	0.911	0.003 (− 0.05, 0.06)
Disease type**	0.075	−0.37 (− 0.77, 0.04)	0.040	−0.05 (−0.10, −0.002)	0.052	−0.48 (−0.96, 0.005)
Age at baseline, years	0.015	0.02 (0.004, 0.03)	0.047	0.015 (0.0002, 0.03)	0.026	0.02 (0.002, 0.04)
Anticentromere antibody	0.137	−0.46 (− 1.06, 0.15)	0.043	−0.033 (− 0.07, −0.001)	0.042	−0.65 (− 1.27, −0.02)
Anti–topoisomerase I antibody	0.291	0.30 (−0.25, 0.84)	0.409	0.02 (− 0.02, 0.05)	0.521	0.22 (− 0.45, 0.88)
Anti–RNA polymerase III antibody	0.071	0.44 (−0.04, 0.92)	0.120	0.03 (− 0.009, 0.08)	0.030	0.66 (0.06, 1.27)
Anti–U1 RNP antibody	0.962	0.02 (− 0.63, 0.66)	0.538	0.009 (− 0.02, 0.04)	0.478	0.31 (− 0.55, 1.17)

^*CRP = C-reactive protein; 95% CI = 95% confidence interval.

^†P value from univariable model.

^‡P value from multivariable model after adjustment for age at enrollment, sex, ethnicity, and body mass index.

^§P value from univariable model when patients on immunosuppressive agents were excluded.

^¶Disease duration calculated from the onset of the first non–aynaud's phenomenon symptom.

^#Disease duration calculated from the onset of the first systemic sclerosis symptom, including Raynaud's phenomenon.

^**Based on the extent of skin disease (limited versus diffuse).